Indian Immunologicals issues statement on Abhayrab vaccine and Australian advisory – Express Pharma Home Latest Updates Indian Immunologicals issues statement on Abhayrab vaccine and Australian advisory Source link
PharmTech connected recently with Henrik Johanning, senior vice president, Quality & Strategy, Epista Life Science, to look back at 2025 and ahead into 2026. Johanning details major European regulatory and manufacturing trends transitioning from 2025 into 2026, focusing on the operationalization of modern quality risk management (QRM) and tangible upgrades required for facilities to achieve…
A look back at the top 10 PharmTech videos of 2025 reveals several overarching themes dominating the pharmaceutical industry landscape, primarily centered on advancing complex therapeutic modalities, navigating stringent regulatory environments, and accelerating development through technological integration. A significant focus across these videos was on specialized medicines, including gene therapies using adeno-associated virus (AAV) vectors,…
Ending the Affordable Care Act wouldn’t fix American healthcare — it would destabilize it. The ACA put a bare floor under coverage, costs, and protections. Removing it would push people back into medical risk markets, raise premiums, shift costs to households and employers, increase emergency care use, and make the entire system more expensive and…
New Delhi: Improving access to new age medicines for obesity and diabetes over the next few years would be a key enabler for the growth of the domestic pharmaceutical industry, according to Sun Pharma Managing Director Kirti Ganorkar. Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs that treat type 2 diabetes, high blood sugar, and obesity…
In September 2025, PharmTech® published the first of what became a three-part series on setting expectations for agentic AI in the pharmaceutical industry, authored by Jason Bryant, senior vice-president of Product Management—AI at ArisGlobal. As 2025 turns to 2026, PharmTech® has interviewed Bryant for a video supplement to these articles, which will again be published…
The year 2025 was defined by escalating global trade tensions that fundamentally reshaped the pharmaceutical supply chain, forcing major companies to commit billions to domestic manufacturing to avoid crippling import tariffs (Infographic – article continues below). What was the immediate aftershock, and what major investment pledges followed? The year opened with immediate policy shifts targeting…
An oral formulation of Wegovy may facilitate initiation of treatment for some patients, particularly those who dislike injections. However, the primary reason most patients stop GLP-1 therapy is not the delivery method — it’s the side effects. Nausea, GI issues, and overall tolerability remain the most significant barriers to long-term adherence. A pill may improve…
December 27, 2025 Table of Contents Understanding Omega-3 Fatty Acids: EPA, DHA, and ALA Why the Source of Omega-3 Matters? Fish Oil: Source, Composition, and Absorption Scientific Evidence and Clinical Understanding Algae Oil: Direct-from-Source Omega-3 Sustainability of Fish Oil and Algae Oil in 2025 Safety, Purity, and Quality Control Clinical Evidence: Established vs Emerging Research…
December 27, 2025 Table of Contents EU GDP Expectations for Prevention of Falsified Medicines MVS Pharma’s Risk-Based Approach to Falsified Medicines Prevention Controlled Handling of Suspected Falsified Medicines Continuous Awareness and Preventive Controls Conclusion The prevention of falsified medicines is a critical responsibility under the EU Good Distribution Practice (GDP) Guidelines. Falsified medicinal products pose…